Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE2/PHASE3
Total Enrollment
100 participants
Study Classification
INTERVENTIONAL
Study Start Date
2011-03-31
Study Completion Date
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Treatment of coronary artery disease is a major health care problem across the entire word, and the United States. Unfortunately, despite a number of medical advances, diagnostic procedure, or epidemiological studies, the treatment of these patients remain complex, and and at times frustrating. In fact, the COURAGE trial conducted in 50 centers across United States and Canada documented that drug treatment, coronary interventions or both were not effective solution in coronary artery diseases.
A novel approach has recently been developed, based on the critical role of the potassium (K) content in red-blood-cell in myocardial oxygenation, since oxygen and K binding by hemoglobin (red-blood-cell) occurs simultaneously in blood passing through the lungs, whereas in the organs as the heart, the hemoglobin release both Oxygen and K ions.
This apparently simple mechanisms occurs in human blood in all individuals but could be altered in subjects with acquired or hereditable defect in red-blood-cell K content, as in hypertensives or CAD patients.
A novel approach has recently been developed, based on the critical role of the potassium (K) content in red-blood-cell in myocardial oxygenation, since oxygen and K binding by hemoglobin (red-blood-cell) occurs simultaneously in blood passing through the lungs, whereas in the organs as the heart, the hemoglobin release both Oxygen and K ions.
This apparently simple mechanisms occurs in human blood in all individuals but could be altered in subjects with acquired or hereditable defect in red-blood-cell K content, as in hypertensives or CAD patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Coronary Heart Disease With Amiloride
NCT01231165
Coronary Heart Disease
COMPLETED
PHASE2/PHASE3
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
NCT02157506
Heart Failure
Decompensated Heart Failure
Acute Heart Failure
COMPLETED
PHASE2
Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
NCT01396395
Stable Angina
Coronary Disease
COMPLETED
PHASE4
Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)
NCT00568594
Coronary Heart Disease
COMPLETED
PHASE1/PHASE2
A Study of CLR325 in Chronic Stable Heart Failure Patients.
NCT02696967
Chronic Stable Heart Failure
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Treatment of Cardiovascular Diseases (CVD) is a major health care problem across the entire word, and particularly in the United States. In fact, these life-threatening disorders are a major cause of emergency medical care and hospitalization in the United States, and according the National Center for Health Statistics (NCHS) there were approximately 1,565,000 hospitalizations for primary or secondary diagnosis of an acute coronary syndrome (ACS), 669,000 for unstable angina (UA) and 896,000 for myocardial infarction (MI). In the 2003, NCHS reported 4,497,000 visits to emergency departments for primary diagnosis of CVD, wherein the average age of a person having a first heart attack is calculated at 65.8 years for men and 70.4 years for women.
Further studies provided by the Heart Disease and Stroke Statistics-2007 Update, of the American Heart Association, reported an estimated 79 400 000 American adults (1 in 3) have 1 or more types of CVD. Of these, and 37 500 000 are estimated to be age 65 or older. As a separate diagnosis, high blood pressure or hypertension, accounts for approximately 72 000 000 of patients (defined as systolic pressure 140 mm Hg or greater and/or diastolic pressure 90 mm Hg or greater, taking antihypertensive medication), coronary heart disease (CHD) for approximately 15 800 000 patients, myocardial infarction for approximately 7 900 000 patients, and angina pectoris (chest pain secondary to ischemic heart disease) for approximately 8 900 000 patients.
Although the treatment of angina (chest pain secondary to ischemic heart disease and one of the most common and early symptom of coronary artery disease) can be tracked as far as 1880's, it still represents a medically unresolved problem. Indeed, treatment of angina in particular, as well as associated condition as ACS, UA, and MI, involves a large number of life-style change recommendations, dietetic advice, drugs, coronary artery intervention, or coronary bypass surgery aimed to improve symptoms, quality of life of patients, and even primary or secondary prevention of the CVD. Unfortunately, despite a century of medical advances and epidemiological studies, the current approach to CVD, and coronary artery disease remain complex, and at times frustrating.
Among some of the proposals to combat CVD, have included the single "polypill"(aspirin + statin + 3 blood pressure lowering agents in half dose, and folic acid) as a strategy to reduce CVD by more than 80% remains presently unresolved, regression of coronary atherosclerosis by using Simvastatin and intravascular ultrasound study was determined to be unpractical. It remains to be determined whether these changes will translate to meaningful reductions in clinical events, or whether new antithrombotic agents for these CVD patients can provide an adequate solution. However, the overarching determination in view of the purported successes to date remains whether these results in highly selected patient populations can be matched to the real-world treatment of acute coronary syndromes.
In a recent study called the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) conducted in 50 hospital centers across the United States and Canada showed that optimal drug treatment with percutaneous coronary interventions (PCI) for stable coronary artery disease, was not more effective than optimal medical therapy alone for preventing cardiovascular events, hospitalization or death, suggesting that drugs, surgical procedures or both were not a statistically effective solution for CHD.
For more than a century, hemodynamic mechanisms involving the coupled tissue O2/CO2 gas exchange and ion H/K transport by Hemoglobin (Hb) in red blood cells (RBC) have been well known to the scientific community, and has been termed the so-called Bohr/Haldane Effect. Data to date has been shown that the RBC has a number of critical roles in maintaining normal vascular function, blood flow, tissue oxygenation and acid-base regulation. These critical roles, including the nitric oxygen (NO) transport, NO synthetase expression, platelet aggregation, vascular rheology, and endothelial function, have been the subject of extensive studies by many investigators. Unfortunately, and despite such multiple integrated functions to maintain tissue oxygenation in health and diseases states, the role of RBC has never been of interest in the therapeutic approach of patients with CHD, specially the ischemic condition of ACS, UA or MI.
In this context, the evidence from our laboratory that erythrocytes have a critical role in body K homeostasis, along with the finding of a hereditable defect in erythrocyte K uptake in hypertensives, and 46% of their normotensive (adolescents, young adults) offspring, led us to assess whether a defective K uptake could impair the regulation of H/K exchange and oxygen delivery in CAD. Since then, a Patent Application whose filed in the USPTO,and a simple medical device for intracellular K measurement in red blood cell by miniature K and Na ion-selective electrode was proposed in conjunction with the University of Michigan.
Although many drugs were tested in order to improve or correct the defective red cell K transport, the most promising compound was the 3,5-diamino-6-chloro-N- \[diaminomethylene\]pyrazinecarboxamide dihydrate derivative, amiloride hydrochloride recently published as a new drug patent application.
The drug originally tested in hypertensives with low RBC K uptake, independently of cell Na content, dietary intake or drugs, became an effective and predictable method to improve RBC K homeostasis that is critically related to other red-cell functions, such as the pH regulation and oxygen delivery. More important, the observation that reversal of the abnormal RBC K content was associated with a decline and better control of BP, fasting plasma glucose, and regression of ST-T alteration related to LVH or CHD, led us to evaluate the role of RBC in the mechanism of H/K exchange, tissue oxygenation in health and disease states.
This Clinical Trial will address the effects of Amiloride in RBC K uptake, and consequently the simultaneous tissue H/K and O2/CO2 exchange, its therapeutic effect on BP control and possible improvement on Angina, Duke Treadmill Score, and ST-T alteration of LVH or CAD.
METHODS OF TREATMENT
Each patient will be prospectively evaluated in order to assess the effects of Amiloride on reversion of angina and ECG alterations of ischemia in CAD. After written consent, the subject will enter the Double-Blind trial of Amiloride Vs Placebo along whit the optimal treatment for Angina and CHD. Amiloride (5 to 10 mg) will be given daily, before breakfast, while other medication for angina, and associated diseases as hypertension or diabetes, were continued. Each patient will be clinically evaluated for angina, dyspnea, or arrhythmias at 1-week, 1, 3, 6 months period. Serial ECG, Ion Transport Studies, BIA, non-invasive hemodynamic and clinical biochemistry will be obtained at 1, 3, 6 months follow-up period. Echocardiograms were obtained basal and 6- months period. In this trial, each subject with plasma ionized calcium (≤1.0 mmol/l) will received 1g of Ca- gluconolactate until the level was ≥1.0 mmol/l.
Following the first 3-month trial, patients with reversion of angina and improvement of ECG abnormalities of ischemia will have low doses of amiloride (5 to 7.5 mg), while nitrates, B-blockers or Calcium Channel Blockers will be progressively discontinued, if no evidence of angina occurred, and if no new no ECG ST-T alteration of ischemia developed. Therefore, amiloride with/without aspirin, Statins and medication for hypertension or diabetes, will be the established treatment until the end of trial.
Further studies provided by the Heart Disease and Stroke Statistics-2007 Update, of the American Heart Association, reported an estimated 79 400 000 American adults (1 in 3) have 1 or more types of CVD. Of these, and 37 500 000 are estimated to be age 65 or older. As a separate diagnosis, high blood pressure or hypertension, accounts for approximately 72 000 000 of patients (defined as systolic pressure 140 mm Hg or greater and/or diastolic pressure 90 mm Hg or greater, taking antihypertensive medication), coronary heart disease (CHD) for approximately 15 800 000 patients, myocardial infarction for approximately 7 900 000 patients, and angina pectoris (chest pain secondary to ischemic heart disease) for approximately 8 900 000 patients.
Although the treatment of angina (chest pain secondary to ischemic heart disease and one of the most common and early symptom of coronary artery disease) can be tracked as far as 1880's, it still represents a medically unresolved problem. Indeed, treatment of angina in particular, as well as associated condition as ACS, UA, and MI, involves a large number of life-style change recommendations, dietetic advice, drugs, coronary artery intervention, or coronary bypass surgery aimed to improve symptoms, quality of life of patients, and even primary or secondary prevention of the CVD. Unfortunately, despite a century of medical advances and epidemiological studies, the current approach to CVD, and coronary artery disease remain complex, and at times frustrating.
Among some of the proposals to combat CVD, have included the single "polypill"(aspirin + statin + 3 blood pressure lowering agents in half dose, and folic acid) as a strategy to reduce CVD by more than 80% remains presently unresolved, regression of coronary atherosclerosis by using Simvastatin and intravascular ultrasound study was determined to be unpractical. It remains to be determined whether these changes will translate to meaningful reductions in clinical events, or whether new antithrombotic agents for these CVD patients can provide an adequate solution. However, the overarching determination in view of the purported successes to date remains whether these results in highly selected patient populations can be matched to the real-world treatment of acute coronary syndromes.
In a recent study called the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) conducted in 50 hospital centers across the United States and Canada showed that optimal drug treatment with percutaneous coronary interventions (PCI) for stable coronary artery disease, was not more effective than optimal medical therapy alone for preventing cardiovascular events, hospitalization or death, suggesting that drugs, surgical procedures or both were not a statistically effective solution for CHD.
For more than a century, hemodynamic mechanisms involving the coupled tissue O2/CO2 gas exchange and ion H/K transport by Hemoglobin (Hb) in red blood cells (RBC) have been well known to the scientific community, and has been termed the so-called Bohr/Haldane Effect. Data to date has been shown that the RBC has a number of critical roles in maintaining normal vascular function, blood flow, tissue oxygenation and acid-base regulation. These critical roles, including the nitric oxygen (NO) transport, NO synthetase expression, platelet aggregation, vascular rheology, and endothelial function, have been the subject of extensive studies by many investigators. Unfortunately, and despite such multiple integrated functions to maintain tissue oxygenation in health and diseases states, the role of RBC has never been of interest in the therapeutic approach of patients with CHD, specially the ischemic condition of ACS, UA or MI.
In this context, the evidence from our laboratory that erythrocytes have a critical role in body K homeostasis, along with the finding of a hereditable defect in erythrocyte K uptake in hypertensives, and 46% of their normotensive (adolescents, young adults) offspring, led us to assess whether a defective K uptake could impair the regulation of H/K exchange and oxygen delivery in CAD. Since then, a Patent Application whose filed in the USPTO,and a simple medical device for intracellular K measurement in red blood cell by miniature K and Na ion-selective electrode was proposed in conjunction with the University of Michigan.
Although many drugs were tested in order to improve or correct the defective red cell K transport, the most promising compound was the 3,5-diamino-6-chloro-N- \[diaminomethylene\]pyrazinecarboxamide dihydrate derivative, amiloride hydrochloride recently published as a new drug patent application.
The drug originally tested in hypertensives with low RBC K uptake, independently of cell Na content, dietary intake or drugs, became an effective and predictable method to improve RBC K homeostasis that is critically related to other red-cell functions, such as the pH regulation and oxygen delivery. More important, the observation that reversal of the abnormal RBC K content was associated with a decline and better control of BP, fasting plasma glucose, and regression of ST-T alteration related to LVH or CHD, led us to evaluate the role of RBC in the mechanism of H/K exchange, tissue oxygenation in health and disease states.
This Clinical Trial will address the effects of Amiloride in RBC K uptake, and consequently the simultaneous tissue H/K and O2/CO2 exchange, its therapeutic effect on BP control and possible improvement on Angina, Duke Treadmill Score, and ST-T alteration of LVH or CAD.
METHODS OF TREATMENT
Each patient will be prospectively evaluated in order to assess the effects of Amiloride on reversion of angina and ECG alterations of ischemia in CAD. After written consent, the subject will enter the Double-Blind trial of Amiloride Vs Placebo along whit the optimal treatment for Angina and CHD. Amiloride (5 to 10 mg) will be given daily, before breakfast, while other medication for angina, and associated diseases as hypertension or diabetes, were continued. Each patient will be clinically evaluated for angina, dyspnea, or arrhythmias at 1-week, 1, 3, 6 months period. Serial ECG, Ion Transport Studies, BIA, non-invasive hemodynamic and clinical biochemistry will be obtained at 1, 3, 6 months follow-up period. Echocardiograms were obtained basal and 6- months period. In this trial, each subject with plasma ionized calcium (≤1.0 mmol/l) will received 1g of Ca- gluconolactate until the level was ≥1.0 mmol/l.
Following the first 3-month trial, patients with reversion of angina and improvement of ECG abnormalities of ischemia will have low doses of amiloride (5 to 7.5 mg), while nitrates, B-blockers or Calcium Channel Blockers will be progressively discontinued, if no evidence of angina occurred, and if no new no ECG ST-T alteration of ischemia developed. Therefore, amiloride with/without aspirin, Statins and medication for hypertension or diabetes, will be the established treatment until the end of trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Coronary Artery Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Amiloride,nitrates,clopidogrel,aspirin
Comparative Efficacious Research
Group Type
EXPERIMENTAL
amiloride
Intervention Type
DRUG
5mg/daily for 12 months
Placebo,nitrates,clopidogrel,aspirin
Comparative Efficacious Research
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Placebo 5mg/daily for 12 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo 5mg/daily for 12 months
Intervention Type
DRUG
amiloride
5mg/daily for 12 months
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
nitrates (40mg/daily for 12 months)
clopidogrel(75mg/daily for 12 months)
aspirin (80mg/daily for 12 months)
nitrates (40mg/daily for 12 months)
clopidogrel(75mg/daily for 12 months)
aspirin (80mg/daily for 12 months)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or female, age 35-75 years having angina (Canada Cardiovascular Society Class II-IV)
2. Essential Hypertension defined as taking at least 1 anti-hypertensive medication, or average systolic blood pressure ≥140 mm Hg, or diastolic blood pressure ≥90 mmHg
3. ST-T changes of LVH (Romhilt-Estes or Framingham Heart Study criteria, with typical LV strain pattern, or isoelectric, inverted or biphasic T waves)
4. ST-T changes of ischemia in resting ECG (ST depression, isoelectric, biphasic, negative or inverted T-waves)
5. Serum potassium \< 5.0 mmol/L prior to randomization
6. Negative pregnancy test in child-bearing potential women
7. Willing to comply with scheduled visits
8. Informed consent form signed by the subject
2. Essential Hypertension defined as taking at least 1 anti-hypertensive medication, or average systolic blood pressure ≥140 mm Hg, or diastolic blood pressure ≥90 mmHg
3. ST-T changes of LVH (Romhilt-Estes or Framingham Heart Study criteria, with typical LV strain pattern, or isoelectric, inverted or biphasic T waves)
4. ST-T changes of ischemia in resting ECG (ST depression, isoelectric, biphasic, negative or inverted T-waves)
5. Serum potassium \< 5.0 mmol/L prior to randomization
6. Negative pregnancy test in child-bearing potential women
7. Willing to comply with scheduled visits
8. Informed consent form signed by the subject
Exclusion Criteria
1. Resistance hypertension despite 3-drugs treatment
2. Myocardial infarction in past 90 days
3. Coronary artery bypass graft surgery in past 90 days
4. Atrial fibrillation with a resting heart rate \> 90 bpm
5. Percutaneous coronary intervention in past 30 days
6. Implanted Pacemaker
7. Stroke in past 90 days
8. Left or Right Ventricular Branch Block
9. Aldosterone antagonist or K sparing drug in last 7 days
10. Intolerance to amiloride
11. Lithium use
12. Current participation in any other therapeutic trial
13. Any condition that may prevent the subject from adhering to the trial protocol
14. History of hyperkalemia (K ≥5.5 mmol/L) in the past six months or K \>5.0 mmol/L within 2 weeks
15. Chronic renal dysfunction
16. Liver disease
17. Chronic pulmonary disease
18. Significant uncorrected valvular heart disease
2. Myocardial infarction in past 90 days
3. Coronary artery bypass graft surgery in past 90 days
4. Atrial fibrillation with a resting heart rate \> 90 bpm
5. Percutaneous coronary intervention in past 30 days
6. Implanted Pacemaker
7. Stroke in past 90 days
8. Left or Right Ventricular Branch Block
9. Aldosterone antagonist or K sparing drug in last 7 days
10. Intolerance to amiloride
11. Lithium use
12. Current participation in any other therapeutic trial
13. Any condition that may prevent the subject from adhering to the trial protocol
14. History of hyperkalemia (K ≥5.5 mmol/L) in the past six months or K \>5.0 mmol/L within 2 weeks
15. Chronic renal dysfunction
16. Liver disease
17. Chronic pulmonary disease
18. Significant uncorrected valvular heart disease
Minimum Eligible Age
35 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinical Research Unit at the Instituto Docente de Urologia
UNKNOWN
Sponsor Role
collaborator
Northern Metropolitan Hospital
UNKNOWN
Sponsor Role
collaborator
Venezuelan Foundation of Heart Failure
OTHER
Sponsor Role
collaborator
University of Carabobo
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antonio Delgado Leon, MD
Prof. of Medicine, MD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Antonio J Delgado-Leon, MD
Role: STUDY_CHAIR
University of Carabobo
Carlos L Delgado-Leon, MD
Role: STUDY_DIRECTOR
Venezuelan Foundation of Heart Failure
Antonio R Delgado-Almeida, MD, FAHA, FACC, APS
Role: PRINCIPAL_INVESTIGATOR
Clinical Research Unit at Docent Institute of Urology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hypertension Research Unit
Valencia, Carabobo, Venezuela
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Venezuela
References
Explore related publications, articles, or registry entries linked to this study.
Delgado-Almeida A. Assessing cell K physiology in hypertensive patients. A new clinical and methodologic approach. Am J Hypertens. 2006 Apr;19(4):432-6. doi: 10.1016/j.amjhyper.2005.09.013.
Reference Type
BACKGROUND
Delgado MC, Delgado-Almeida A. Red blood cell K+ could be a marker of K+ changes in other cells involved in blood pressure regulation. J Hum Hypertens. 2003 May;17(5):313-8. doi: 10.1038/sj.jhh.1001527.
Reference Type
BACKGROUND
Delgado-Almeida A. Unexpected therapeutic response to spironolactone: a prospective debate on aldosterone and potassium ion in hypertension. Hypertension. 2007 Nov;50(5):e164-5; author reply e166. doi: 10.1161/HYPERTENSIONAHA.107.099408. Epub 2007 Sep 10. No abstract available.
Reference Type
BACKGROUND
Delgado-Almeida A. Reinterpreting sodium-potassium data in salt-sensitivity hypertension: a prospective debate. Hypertension. 2005 Feb;45(2):e4; author reply e4. doi: 10.1161/01.HYP.0000154194.49725.b7. No abstract available.
Reference Type
BACKGROUND
Delgado-Almeida A. Critical value of the electrocardiogram in LVH: from predictive index to therapeutic reassessment. Hypertension. 2005 Feb;45(2):e6; author reply e6. doi: 10.1161/01.HYP.0000151782.93734.de. No abstract available.
Reference Type
BACKGROUND
Delgado MC, Delgado-Almeida A. Red blood cell potassium and blood pressure in adolescents: a mixture analysis. Nutr Metab Cardiovasc Dis. 2002 Jun;12(3):112-6.
Reference Type
BACKGROUND
Delgado MC, Delgado-Almeida A. Abnormal Potassium. In: Mohler III ER, Townsend RR (eds). Advanced Therapy in Hypertension and Vascular Disease. BC Decker Inc. Publisher, Ontario, Canada. 2006:291-296.
Reference Type
BACKGROUND
Weder AB, Delgado MC, Zhu X, Gleiberman L, Kan D, Chakravarti A. Erythrocyte sodium-lithium countertransport and blood pressure: a genome-wide linkage study. Hypertension. 2003 Mar;41(3 Pt 2):842-6. doi: 10.1161/01.HYP.0000048703.16933.6D. Epub 2002 Dec 23.
Reference Type
BACKGROUND
Delgado MC. Potassium in hypertension. Curr Hypertens Rep. 2004 Feb;6(1):31-5. doi: 10.1007/s11906-004-0008-6.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UIC-3 2007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina
NCT00682565
COMPLETED
PHASE2
Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg
NCT00272805
COMPLETED
PHASE3
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
NCT05350969
COMPLETED
PHASE2
Effect of Ranolazine on Valvular Disease in Patients With Pacemakers
NCT01979965
UNKNOWN
PHASE4
The Effect of Nicorandil on Left Ventricular Myocardial Strain in Patients With Coronary Chronic Total Occlusion
NCT05087797
COMPLETED
PHASE4
Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
NCT02617550
COMPLETED
PHASE1
Efficacy Study of Hydroxychloroquine to Treat High-risk Coronary Artery Disease.
NCT02874287
COMPLETED
PHASE4
A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure
NCT00323037
COMPLETED
PHASE3
Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461
NCT02329184
COMPLETED
PHASE1
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
NCT02840565
COMPLETED
PHASE1
Clinical Study to Assess Safety, PK and PD Parameters of CDR132L
NCT04045405
COMPLETED
PHASE1
Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker
NCT01945606
COMPLETED
PHASE2
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
NCT05724121
RECRUITING
A Randomized, Placebo-Controlled, Double-Blind, Double Dummy Trial To Determine The Relative Effect Of Pm101 Versus Placebo And Amiodarone IV On Blood Pressure In Subjects With Stable Congestive Heart Failure
NCT00739193
WITHDRAWN
PHASE2
An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia
NCT05117346
COMPLETED
PHASE1/PHASE2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180
NCT00907998
COMPLETED
PHASE1
Beta-Blocker Heart Attack Trial (BHAT)
NCT00000492
COMPLETED
PHASE3
Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI
NCT06787430
NOT_YET_RECRUITING
PHASE4
Ranolazine Implantable Cardioverter-Defibrillator Trial
NCT01215253
COMPLETED
PHASE3
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
NCT05305911
RECRUITING
PHASE2
Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy
NCT00281255
WITHDRAWN
PHASE1/PHASE2
Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy
NCT05795400
ACTIVE_NOT_RECRUITING
NA
A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction
NCT02742103
COMPLETED
PHASE2
N-of-1 for Beta-Blockers in Cardiac Amyloidosis
NCT05019027
ENROLLING_BY_INVITATION
PHASE4